Fig. 7: Impacts of VP24 mutants on infectious VLP production.
From: Structural basis for Ebola virus nucleocapsid assembly and function regulated by VP24
a iVLP production using VP24 mutants. Left panel, cell lysate of plasmid-transfected P0 cells were analyzed using western blotting using anti-NP, -VP24, -VP35, and -VP40 antibodies. Beta-actin was detected as a loading control. Right panel, purified iVLPs from the supernatants of P0 cells were analyzed using western blotting. b Luciferase activity on P1 cells infected with respective iVLPs. The results are presented in box-and-whiskers plots. The plots detail the maxima, 75th percentile, median, 25th percentile, and minima, with outliers represented by dots. The activities are compared between Wild-type VP24 and its mutants, with the activity of VP24 wild-type normalized to 100%. n = 3 for each technical replicate. All experiments were performed in three biological replicates (n = 9 in total). p values from ANOVA-Dunnett’s test are indicated as ***p <0.001, **p <0.01, *p < 0.05. ***p <0.001. iVLP infectious virus-like particle, NP nucleoprotein. Source data are provided as a Source data file.
